A Game-Changer for Diabetes: Polymer Delivers Insulin Painlessly Through Skin
November 25, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Steglatro
Synonyms :
ertugliflozin
Class :
SGLT2 Inhibitors, Antidiabetics
Brand Name :
Steglatro
Synonyms :
ertugliflozin
Class :
SGLT2 Inhibitors, Antidiabetics
Dosage Forms & StrengthsÂ
TabletÂ
5mgÂ
15mgÂ
Initial dose-5mg orally in the morning daily
Maintenance doe-Can increase the dose up to 15mg every day.
Safety and efficacy not established.Â
No Dose Adjustment is Necessary After 65 Years of Age Â
Patients over 65 were more likely to have adverse effects from volume depletion than younger patients.Â
may increase the Glucose-lowering effect of SGLT2 Inhibitors
may increase the Glucose-lowering effect of SGLT2 Inhibitors
may increase the Glucose-lowering effect of SGLT2 Inhibitors
may increase the Glucose-lowering effect of SGLT2 Inhibitors
may increase the Glucose-lowering effect of SGLT2 Inhibitors
may increase the Glucose-lowering effect of SGLT2 Inhibitors
may increase the Glucose-lowering effect of SGLT2 Inhibitors
may increase the Glucose-lowering effect of SGLT2 Inhibitors
may increase the Glucose-lowering effect of SGLT2 Inhibitors
may increase the Glucose-lowering effect of SGLT2 Inhibitors
relugolix/​estradiol/​norethindrone
may increase the Glucose-lowering effect of Agents with Blood Glucose Lowering Effects
relugolix/estradiol/norethindrone
may increase the Glucose-lowering effect of Agents with Blood Glucose Lowering Effects
may increase the Glucose-lowering effect of Agents with Blood Glucose Lowering Effects
may increase the Glucose-lowering effect of Agents with Blood Glucose Lowering Effects
may increase the Glucose-lowering effect of Agents with Blood Glucose Lowering Effects
may increase the Glucose-lowering effect of Antidiabetic Agents
may increase the Glucose-lowering effect of Antidiabetic Agents
may increase the Glucose-lowering effect of Antidiabetic Agents
may increase the Glucose-lowering effect of Antidiabetic Agents
may increase the Glucose-lowering effect of Antidiabetic Agents
may increase the Glucose-lowering effect of Antidiabetic Agents
may increase the Glucose-lowering effect of Antidiabetic Agents
may increase the Glucose-lowering effect of Antidiabetic Agents
may increase the Glucose-lowering effect of Antidiabetic Agents
may increase the Glucose-lowering effect of Antidiabetic Agents
may increase the Glucose-lowering effect of Antidiabetic Agents
may increase the Glucose-lowering effect of Agents with Blood Glucose Lowering Effects
may increase the Glucose-lowering effect of Agents with Blood Glucose Lowering Effects
may increase the Glucose-lowering effect of Agents with Blood Glucose Lowering Effects
may increase the Glucose-lowering effect of Agents with Blood Glucose Lowering Effects
may increase the Glucose-lowering effect of Agents with Blood Glucose Lowering Effects
may increase the Glucose-lowering effect of Agents with Blood Glucose Lowering Effects
may increase the Glucose-lowering effect of Agents with Blood Glucose Lowering Effects
choline magnesium trisalicylate
may increase the Glucose-lowering effect of Agents with Blood Glucose Lowering Effects
may increase the Glucose-lowering effect of Agents with Blood Glucose Lowering Effects
may increase the Glucose-lowering effect of Agents with Blood Glucose Lowering Effects
may increase the Glucose-lowering effect of Agents with Blood Glucose Lowering Effects
may increase the Glucose-lowering effect of Agents with Blood Glucose Lowering Effects
may increase the Glucose-lowering effect of Agents with Blood Glucose Lowering Effects
may decrease the therapeutic effect of Antidiabetic Agents
may decrease the therapeutic effect of Antidiabetic Agents
When halometasone is used together with ertugliflozin, this leads to elevated risk or seriousness of hyperglycemia
When ertugliflozin is used together with diazoxide, this leads to reduction in therapeutic effectiveness of ertugliflozin
methylprednisolone hemisuccinateÂ
When methylprednisolone hemisuccinate is aided with ertugliflozin, this leads to elevated hyperglycemia risk
May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may decrease the therapeutic effect
may increase the hypoglycaemic effect of androgens
Actions and Spectrum:Â
ertugliflozin is a medication used for the treatment of type 2 diabetes mellitus. The mechanism of action of ertugliflozin involves inhibiting the SGLT2 protein in the kidneys, leading to increased urinary excretion of glucose and reduced reabsorption of glucose back into the bloodstream. This results in lower blood glucose levels in individuals with type 2 diabetes.Â
The SGLT2 protein reabsorbs glucose from the kidney tubules back into the bloodstream. By inhibiting this protein, ertugliflozin eliminates excess glucose from the body through urine, thus reducing blood glucose levels.Â
ertugliflozin has a spectrum of activity primarily related to its ability to lower blood glucose levels. It is effective in treating type 2 diabetes mellitus as a monotherapy and in combination with other antidiabetic medications such as metformin, sulfonylureas, and insulin.Â
Frequency definedÂ
>10%Â
Female genital mycotic infections (9.1-12.2%)Â
1-10%Â
Male genital mycotic infections (3.7-4.2%)Â
Headache (2.9-3.5%)Â
Increased urination (2.4-2.7%)Â
Back pain (1.7-2.5%)Â
Weight decreased (1.2-2.4%)Â
Volume depletion adverse effects (1.9-4.4%)Â
Urinary tract infections (4-4.1%)Â
Vaginal pruritus (2.4-2.8%)Â
Nasopharyngitis (2-2.5%)Â
Renal adverse effects (1.3-2.5%)Â
Thirst (1.4-2.7%)Â Â
Post marketing reportsÂ
AngioedemaÂ
Necrotizing fasciitis of the perineumÂ
Black box warning:Â
NoneÂ
Contraindications/caution:Â
Contraindications:Â
HypersensitivityÂ
Caution:Â
Pregnancy consideration: Insufficient data availableÂ
Lactation: Excretion of the drug in human breast milk is unknownÂ
Pregnancy category:Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.Â
<b>Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this categoryÂ
Pharmacology:Â
ertugliflozin works by inhibiting the SGLT2 protein in the kidneys. SGLT2 is responsible for reabsorbing glucose from the glomerular filtrate into the bloodstream. By inhibiting SGLT2, ertugliflozin reduces glucose reabsorption, increasing glucose excretion in the urine. This mechanism helps lower blood glucose levels in patients with type 2 diabetes.Â
Pharmacodynamics:Â
Pharmacokinetics:Â
AbsorptionÂ
ertugliflozin is well absorbed from the gastrointestinal tract after oral administration. The peak plasma concentration is achieved within 1 hour under fasting conditions and 2 hours when taken with a high-fat, high-calorie meal. Bioavailability is approximately 100% for a 15 mg dose.Â
Â
DistributionÂ
ertugliflozin has a relatively large volume of distribution at a steady-state (Vd) of 85.5 L. It is highly protein-bound, with approximately 93.6% bound to plasma proteins. The blood-to-plasma concentration ratio of ertugliflozin is 0.66.Â
MetabolismÂ
The major metabolic pathway for ertugliflozin involves glucuronidation mediated by UGT1A9 and UGT2B7 enzymes. This metabolic pathway results in the formation of two pharmacologically inactive glucuronide metabolites. The oxidative metabolism of ertugliflozin, mediated by cytochrome P450 (CYP) enzymes, is minimal (approximately 12%).Â
Elimination and ExcretionÂ
The half-life of ertugliflozin is approximately 16.6 hours.Â
The clearance of ertugliflozin is 11.2 L/hr.Â
The primary route of excretion of oral [14C]-ertugliflozin solution is through feces (40.9%) and urine (50.2%).Â
The unchanged form of ertugliflozin is excreted primarily in feces (33.8%) and, to a lesser extent, in urine (1.5%).Â
Administration:Â
Oral administration:Â
Take everyday in the morning, with or without meals. Â
Dose missed Â
Use it immediately Â
You should not take a dosage if it is nearly time for your next scheduled dose.Â
Do not take two ertugliflozin dosages at the same time.Â
Patient information leafletÂ
Generic Name: ertugliflozinÂ
Why do we use ertugliflozin?Â
ertugliflozin is used for the management of type 2 diabetes mellitus in adults. It is prescribed as an adjunct to diet and exercise to help improve glycemic control. Here are the primary uses of ertugliflozin:Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
